Agios Pharmaceuticals Inc 2025 SR
The report highlights Agios Pharmaceuticals' 2024 progress in developing treatments for rare diseases, including regulatory filings for thalassemia and clinical trials for sickle cell disease. It emphasizes a patient-centric approach, incorporating patient feedback into clinical trial design to improve recruitment and equity. The company maintains a strong focus on employee well-being, offering a flexible work model that has led to high engagement and a diverse workforce, with 50% women on the board. Reporting is aligned with SASB and IFRS S1 standards, reflecting a commitment to transparency and ethical business practices.
Company: Agios Pharmaceuticals Inc
Sector: Health Care
Country: United States
Year: 2025
Type: SR
Pages: 44
Agios Pharmaceuticals Inc
ESG Report
The report highlights Agios Pharmaceuticals' 2024 progress in developing treatments for rare diseases, including regulatory filings for thalassemia and clinical trials for sickle cell disease. It emphasizes a patient-centric approach, incorporating patient feedback into clinical trial design to improve recruitment and equity. The company maintains a strong focus on employee well-being, offering a flexible work model that has led to high engagement and a diverse workforce, with 50% women on the board. Reporting is aligned with SASB and IFRS S1 standards, reflecting a commitment to transparency and ethical business practices.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Sustainable Development Goals
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities